Patent application number | Description | Published |
20100144810 | ANGIOTENSIN II RECEPTOR ANTAGONISTS - A compound having the structure | 06-10-2010 |
20100152258 | ANGIOTENSIN II RECEPTOR ANTAGONISTS - A compound having the structure (Formula I), wherein Y is —Y | 06-17-2010 |
20100152259 | ANGIOTENSIN II RECEPTOR ANTAGONISTS - A compound having the structure (Formula I), wherein R an angiotensin receptor antagonist active group, Y is Y | 06-17-2010 |
20100273845 | ANGIOTENSIN II RECEPTOR ANTAGONISTS - A compound having the structure | 10-28-2010 |
20100292192 | ANGIOTENSIN II RECEPTOR ANTAGONISTS - A compound having the structure | 11-18-2010 |
20100298277 | ANGIOTENSIN II RECEPTOR ANTAGONISTS - A compound having the structure | 11-25-2010 |
20110052674 | ANGIOTENSIN II RECEPTOR BLOCKER DERIVATIVES - New angiotensin II receptor blocker nitroderivatives of general formula (I) and pharmaceutically acceptable salts or stereoisomers thereof: and their use for treating cardiovascular, renal and chronic liver diseases, inflammatory processes and metabolic syndromes. | 03-03-2011 |
20110065765 | ANGIOTENSIN II RECEPTOR ANTAGONISTS - A compound having the structure | 03-17-2011 |
20110201621 | ANGIOTENSIN II RECEPTOR ANTAGONISTS - A compound having the structure | 08-18-2011 |
20110230532 | NITROOXY CYCLOALKANE DERIVATIVES - A compound having the structure wherein Y is selected from the group consisting of —C(O)OR | 09-22-2011 |
20120202845 | DIURETICS - A compound having the structure formula (I) or a pharmaceutically acceptable salt thereof, and methods of using the compounds for treating hypertension. | 08-09-2012 |
20120208838 | DIURETICS - A compound having the structure (I) wherein R is selected from the group consisting of 1) and 2), or a pharmaceutically acceptable salt thereof, and methods of using the compounds for treating hypertension. | 08-16-2012 |
20120232039 | PRIMARY AMINE DIAZENIUMDIOLATE HETEROCYCLIC DERIVATIVES - A compound having the structure | 09-13-2012 |
20120238608 | ANGIOTENSIN II RECEPTOR ANTAGONISTS - A compound having the structure wherein R is, for example, Y is selected from the group consisting of 1) R5, 2) —C(R1R2) (C(R3R4))0-1Y1R5, and 3) —C(R1R2)—O—Y1R5; R1, R2, R3 and R4 are independently selected from the group consisting of hydrogen and C1-4 alkyl; R5 is; Y1 is selected from the group consisting of C(O)—O— and P(O)(OR6)—O—; and R6 is hydrogen or CH3, or a pharmaceutically acceptable salt thereof, and methods of using the compounds for treating hypertension. | 09-20-2012 |
20130053352 | DIAZENIUMDIOLATE CYCLOPENTYL DERIVATIVES - A compound having the structure or a pharmaceutically acceptable salt thereof, wherein R | 02-28-2013 |
20130289003 | DIAZENIUMDIOLATE HETEROCYCLIC DERIVATIVES - A compound having the structure: useful for treating hypertension, Pulmonary Arterial Hypertension (PAH), congestive heart failure, conditions resulting from excessive water retention, cardiovascular disease, diabetes, oxidative stress, endothelial dysfunction, cirrhosis, pre-eclampsia, osteoporosis or nephropathy. | 10-31-2013 |
20130296278 | Diazeniumdiolate Derivatives - A compound having the structure (I) useful for treating hypertension, pulmonary arterial hypertension, congestive heart failure, conditions resulting from excessive water retention, cardiovascular disease, diabetes, oxidative stress, endothelial dysfunction, cirrhosis, pre-eclampsia, osteoporosis or nephropathy. | 11-07-2013 |
20140045819 | ALDOSTERONE SYNTHASE INHIBITORS - This invention relates to tricyclic triazole analogues of the formula I or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthetase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthetase. | 02-13-2014 |
20140088048 | DIAZENIUMDIOLATE CYCLOHEXYL DERIVATIVES - A compound having the structure | 03-27-2014 |